Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people

Julia Hippisley-Cox1, Duncan Young2,3, Carol Coupland4, Keith M Channon5, Pui San Tan6, David A Harrison7, Kathryn Rowan8,  Paul Aveyard6, Ian D Pavord9, Peter J Watkinson5,10Correspondence to Prof Julia Hippisley-Cox, Primary Care Health Sciences, University of Oxford, Oxford OX1  Abstract…[...]

Read More

Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches

Authors: Magda Gioia,a,⁎ Chiara Ciaccio,a,⁎ Paolo Calligari,b Giovanna De Simone,c Diego Sbardella,d Grazia Tundo,dGiovanni Francesco Fasciglione,a Alessandra Di Masi,cD onato Di Pierro,a Alessio Bocedi,b Paolo Ascenzi,c,e and Massimo Colettaa,⁎ Biochem Pharmacol. 2020 Dec;…[...]

Read More

‘Natural Immunity Is Really Better’: New Israeli Study Fuels Debate On Vaccination Versus Natural Immunity

Authors: DYLAN HOUSMAN HEALTHCARE REPORTER August 28, 20215:12 PM ET A new study of the power of COVID-19 natural immunity versus the protection provided by vaccines is igniting further debate…[...]

Read More

“Inescapable” COVID-19 Antibody Discovery – Neutralizes All Known SARS-CoV-2 Strains

Authors: By LAWRENCE BERKELEY NATIONAL LABORATORY AUGUST 26, 2021 An antibody therapy that appears to neutralize all known SARS-CoV-2 strains, and other coronaviruses, was developed with a little help from structural biologist Jay Nix.…[...]

Read More